Superluminal Medicines raised a $60 million Series B to advance its genetic obesity program into Phase 1 testing, a move aimed at validating its approach in the competitive MC4R obesity space. The Boston-based company is joining a wave of therapies seeking to convert genetics into actionable weight-loss biology earlier in development. The financing underscores continued investor appetite for obesity mechanisms tied to upstream hormonal control, particularly where conventional GLP-1 strategies have already expanded the market but leave room for differentiated targets. Phase 1 support also suggests Superluminal is prioritizing safety, pharmacology, and dose-finding to establish a development runway for later-stage efficacy studies. With obesity drugmakers consolidating around increasingly crowded late-stage pipelines, early clinical capital raises can serve as a barometer for which mechanistic bets are most fundable now.